Edgewise Therapeutics specializes in precision small molecule therapies addressing severe muscle diseases through a proprietary drug discovery platform. The company’s lead candidate, sevasemten, targets fast skeletal muscle myosin and is advancing in late-stage trials for Duchenne and Becker muscular dystrophies, supported by multiple FDA designations. Financially, the company continues to report widening operating and net losses driven by increasing R&D spending aligned with clinical development progress. Strong liquidity supports ongoing operations with no dividends or buybacks. Key risks include regulatory hurdles, third-party dependencies, and competition from larger pharma companies.